386 related articles for article (PubMed ID: 19281600)
1. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
2. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
3. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH
Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820
[TBL] [Abstract][Full Text] [Related]
4. The hypoalgesic effect of tramadol in relation to CYP2D6.
Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH
Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065
[TBL] [Abstract][Full Text] [Related]
5. Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.
Arendt-Nielsen L; Olesen AE; Staahl C; Menzaghi F; Kell S; Wong GY; Drewes AM
Anesthesiology; 2009 Sep; 111(3):616-24. PubMed ID: 19672186
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Mikkelsen S; Verstuyft C; Becquemont L; Sindrup SH; Brosen K
Fundam Clin Pharmacol; 2010 Aug; 24(4):517-24. PubMed ID: 19845769
[TBL] [Abstract][Full Text] [Related]
7. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model.
Staahl C; Upton R; Foster DJ; Christrup LL; Kristensen K; Hansen SH; Arendt-Nielsen L; Drewes AM
J Clin Pharmacol; 2008 May; 48(5):619-31. PubMed ID: 18440921
[TBL] [Abstract][Full Text] [Related]
10. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K
Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129
[TBL] [Abstract][Full Text] [Related]
14. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
17. Specific effect of levetiracetam in experimental human pain models.
Enggaard TP; Klitgaard NA; Sindrup SH
Eur J Pain; 2006 Apr; 10(3):193-8. PubMed ID: 15946871
[TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
Koltzenburg M; Pokorny R; Gasser UE; Richarz U
Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study.
Staahl C; Dimcevski G; Andersen SD; Thorsgaard N; Christrup LL; Arendt-Nielsen L; Drewes AM
Scand J Gastroenterol; 2007 Mar; 42(3):383-90. PubMed ID: 17354119
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone alters temporal summation but not conditioned pain modulation: preclinical findings and possible relations to mechanisms of opioid analgesia.
Suzan E; Midbari A; Treister R; Haddad M; Pud D; Eisenberg E
Pain; 2013 Aug; 154(8):1413-8. PubMed ID: 23707271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
